Recruiting

Stasis

Sponsor:

Outliers, Inc.

Code:

NCT07380412

Conditions

ADHD

Sleep Disturbance

Brain Fog

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

Stasis Daytime and Nighttime

Placebo

Study Details

Brief summary:

This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant medications used for ADHD over a three-month period in adults.

Conditions

ADHD

Sleep Disturbance

Brain Fog

Study ID

NCT07380412

Start date

Aug 12, 2025

Status verified date

Jan, 2026

Completion date

Mar, 2026

Anticipated

Primary completion date

Mar, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Aged 18-55 years
  • Currently prescribed stimulant medication for ADHD
  • Experiencing: sleep difficulty, irritability, anxiety, brain fog
  • Stable medication dose ≥3 months
  • Healthy with no uncontrolled chronic conditions
  • Stable on supplements ≥3 months if applicable
  • US resident
  • Willing to maintain current habits

Exclusion Criteria:

  • Chronic conditions (e.g. cancer, mental illness)
  • Use of psychiatric medications besides stimulants
  • Pregnancy, breastfeeding, thyroid, liver, kidney conditions
  • Recent smokers or heavy alcohol use
  • Night shift workers
  • Participation in other clinical trials
  • Allergies to product ingredients

Study Design

Enrollment

90 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Stasis Supplement

placebo comparator: Placebo Comparator

Interventions

Stasis Daytime and Nighttime

Daytime taken with stimulant medication and food. Nighttime taken 30 minutes before bedtime on an empty stomach.

Placebo

Matched placebo product in taste and appearance.

Primary outcome measure

  • Change in oxidative stress and cortisol levels as measured by hs-CRP, 8-OHdG [ Time Frame: Baseline and Month 3 ]
  • Change in cortisol levels [ Time Frame: Baseline and Month 3 ]

Central Contacts and Locations

Central contacts

Patrick Renner, MSc

4242450284hello@citruslabs.com

Locations

Citruslabs

Recruiting

Las Vegas, Nevada, United States, 89118

Contacts

Patrick Renner, MSc

424-245-0284hello@citruslabs.com

More Information

Sponsor

Outliers, Inc.

Last update posted

Feb 2, 2026

Last verified

Jan, 2026

Keywords

  • ADHD
  • Anxiety

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Outliers, Inc. on 2026-02-02.